Full list of publications (Adobe PDF) - Leibniz

FULL PUBLICATIONS:
Garbe E, Suling M, Kloss S, Lindemann C, Schmid U. Linkage of mother-baby pairs in the
German Pharmacoepidemiological Research Database. Pharmacoepidemiol Drug Saf (in
press)
Behr S, Andersohn F, Garbe E. Risk of intracerebral hemorrhage associated with
phenprocoumon exposure: a nested case-control study in a large population-based German
database. Pharmacoepidemiol Drug Saf 2010; 19: 722-30
Andersohn F, Schade R, Willich SN, Garbe E. Use of antiepileptic drugs in epilepsy and the
risk of self harm or suicidal behaviour. Neurology 2010;75: 335-40.
Renoux C, Dell’Aniello S, Garbe E, Suissa S. Transdermal versus oral hormone replacement
therapy and the risk of stroke: nested case-control study. BMJ 2010; 340: c2519
Andersohn F, Waring M, Garbe E. Risk of ischemic stroke in patients with Crohn’s disease:
A population based nested case-control study. Inflammatory Bowel Diseases 2010; 16:138792
Andersohn F, Schmedt N, Weinmann S, Willich SN, Garbe E. Priapism Associated with
Antipsychotics: Role of Alpha-1 Adrenoceptor Affinity. J Clin Psychopharmacol 2010, 30; 6871
Cox E, Martin BC, Van Staa T, Garbe E, Siebert U, Johnson ML. Good research practices
for comparative effectiveness research: approaches to mitigate bias and confounding in the
design of non-randomized studies of treatment effects using secondary data sources. Report
of the ISPOR Retrospective Database Analysis Task Force – Part II. Value in Health 2009;
Sept. 10 (epub ahead of print)
Andersohn F, Konzen C, Bronder E, Klimpel A, Garbe E. Citalopram induced bleeding due to
profound thrombocytopenia. Psychosomatics 2009; 50: 297-298
Spitler LE, Weber RW, Allen RE, Meyer J, Cruickshank S, Garbe E, Lin HY, Soong SJ.
Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF,
Sargramostim) administered for three years as adjuvant therapy of stage II(T4), III, and IV
melanoma. J Immunother 2009, 32: 632-637
Andersohn F, Schade R, Suissa S, Garbe E. Long-term use of antidepressants for
depressive disorders and the risk of diabetes mellitus. Am J Psychiatry 2009; 166: 591-8
Blaschke D, Rolf S, Parwani AS, Huemer M, Dietz R, Garbe E, Haverkamp W. Pharmakainduzierte Herzklappenveränderungen. Dtsch Med Wochenschr 2009; 134: 365-370
Sehouli J, Mahner S, Garbe E, Oskay-Özcelik G. Die ältere Patientin in der Gynäkologischen
Onkologie. Praktische Fortbildung Gynäkologie, Geburtsmedizin und Gynäkologische
Endokrinologie 2008; 4: 264-276
Eisele S, Garbe E, Zeitz M, Schneider T, Somasundaram R. Ciprofloxacin-related acute
severe myalgia necessitating emergency care treatment: a case report and review of the
literature. International Journal of Clinical Pharmacology and Therapeutics 2009; 47: 165168.
Andersohn F, Garbe E. Cardiac and noncardiac fibrotic reactions caused by ergot- and
nonergot-derived dopamine agonists. Movement Disorders 2009; 24:129-33. (IF 4.014)
Renoux C, Dell’Aniello S, Garbe E, Suissa S. Hormone replacement therapy use and the risk
of stroke. Maturitas 2008; 61: 305-309
Hoffmann F, Andersohn F, Giersiepen K, Scharnetzky E, Garbe E: Validierung von
Sekundärdaten - Grenzen und Möglichkeiten (Validation of secondary data – limitations and
opportunities). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2008;
51:1118-26
Andersohn F, Garbe E. Pharmakoepidemiologische Forschung mit Routinedaten des
Gesundheitswesens (Pharmacoepidemiological research with routine healthcare data).
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2008; 51: 1135-44.
Suissa S, Garbe E. Primer: administrative health databases in observational studies of drug
effects - advantages and disadvantages. Nat Clin Pract Rheumatol 2007; 12:725-32.
Garbe E. Non-chemotherapy drug-induced agranulocytosis. Exp Opin Drug Saf 2007; 6:
323-335
Andersohn F, Konzen C, Garbe E. Systematic review: Agranulocytosis induced by
nonchemotherapy drugs. Ann Intern Med 2007; 146: 657-665
Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk
of cardiac valve regurgitation. N Engl J Med 2007; 356: 29-38
Garbe E, Andersohn F. Contraindication labelling changes in the United States and
Germany. Eur J Clin Pharmacol 2007, 63: 87-93
Andersohn F, Schade R, Suissa S, Garbe E. COX-2 selective NSAIDs and the risk of
ischemic stroke: A nested case-control study. Stroke 2006; 37: 1725-30
Andersohn F, Suissa S, Garbe E. Use of first- and second-generation cyclooxygenase-2selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction.
Circulation 2006; 113: 1950-7
Heinemann LA, Garbe E, Lewis M, van der Woude F, Graf H. Case-control study on
analgesics and nephropathy (SAN): protocol. BMC Nephrology 2005; 6: 9
Jochmann N, Stangl K, Garbe E, Baumann G, Stangl V. Female-specific aspects in the
pharmacotherapy of chronic cardiovascular diseases. Eur Hear J 2005, 26: 1585-95
Andersohn F, Bronder E, Klimpel A, Garbe E. The proportion of drug-related serious rare
blood dyscrasias: Estimates from the Berlin Case-Control Surveillance Study. American J
Hematology 2004: 77: 316-8
Andersohn F, Hagmann FG, Garbe E. Thrombotic thrombocytopenic purpura / haemolytic
uraemic syndrome associated with clopidogrel: report of two new cases. Heart 2004; 90: e57
Ahrens N, Schewior L, Garbe E, Kiesewetter H, Salama A. Massive haemolysis after
intramuscular diclofenac in a patient who apparently tolerated oral medication. Vox Sang
2004; 86: 71-74
Garbe E, Meyer O, Andersohn F, Aslan T, Kiesewetter H, Salama A. Amlodipine-induced
immune thrombocytopenia. Vox Sang 2004; 86: 75-76
Garbe E, Suissa S. Issues to debate on the Women's Health Initiative (WHI) study. Hormone
replacement therapy and acute coronary outcomes: Methodological issues between
randomized and observational studies. Human Reproduction 2004; 19: 8-13.
Garbe E, Levesque L, Suissa S: Variability of breast cancer risk in observational studies of
hormone replacement therapy: A meta-regression analysis. Maturitas 2004; 47: 175-83
Klotz U, Beil W, Gleiter C, Drewelow B, Garbe E, Gillessen A, Mutschler E. [Drug
interactions. Mechanisms and clinical relevance]. Internist 2003; 44: 1444-1449
Heinemann K, Moehner S, Lewis M, Assmann A, Garbe E, Heinemann LA. [Trends of OC
use 1980-1999 in a German cohort of women]. Zentralbl Gynakol 2002 ;124:128-31
Heinemann LA, Lewis MA, Kühl-Habich D, Braendle W, Garbe E, Möhner S. [Lifetime history
of oral contraceptive use and development of tumours of the uterus and ovary]. Geburtsh
Frauenheilk 2002, 62: 566-573
Heinemann K, Möhner S, Assmann A, Lewis M, Raff T, Garbe E, Heinemann LA. Trend der
HRT Nutzung in Deutschland 1980-1999. Ergebnisse der Deutschen Kohortenstudie zur
Frauengesundheit. Frauenarzt 2002, 43: 508-511
Meisel C, Garbe E. [Relevance of pharmacogenomic parameters in postmarketing
surveillance]. MedGen 2001, 13: 276-280
Heinemann LAJ, Garbe E, Farmer R, Lewis M. Venous thromboembolism and oral
contraceptive use: a methodological study of diagnostic suspicion and referral bias. Eur J
Contracept Reprod Health Care 2000; 5: 183-191
Garbe E, Heinemann LAJ, Rabe T, Winkler UH. [Non-contraceptive benefits of the pill--an
often neglected fact]. Zentralbl Gynakol 2000, 122: 18-27
Heinemann LAJ, Garbe E, Winkler UH, Rabe T. [German Cohort Study of Women's Health-benefits of oral contraceptives]. Study protocol. Zentralbl Gynakol 2000, 122: 112-115
Garbe E. [Pharmacoepidemiological analysis
glucocorticoids]. Klin Pharmakol akt 2000, 11: 2-5
of
ocular
side
effects
of
inhaled
Follmann M, Heinemann LAJ, Bauerfeind A, Garbe E. Treatment with potentially hepatotoxic
drugs and the risk of hepatocellular carcinoma. Results of a European case-control study.
Pharmacoepidemiol Drug Saf 2000; 9: 417-422
Brockmöller J, Cascorbi I, Meisel C, Kaiser R, Stangl K, Garbe E, Roots I. [Molecular
medicine is reality]. Humboldt-Spektrum 1999, 3: 4-11
Heinemann LAJ, Assmann A, DoMinh T, Garbe E. Oral Progestogen-Only Contraceptives
and Cardiovascular Risk: Results from Transnational Study on Oral Contraceptives and the
Health of Young Women. Transnational Research Group on Oral Contraceptives and the
Health of Young Women. Eur J Contracept Reprod Health Care 1999, 4: 67-73
Garbe E, Boivin J, LeLorier J, Suissa S. Selection of controls in database case-control
studies: Glucocorticoids and the risk of glaucoma. J Clin Epidemiol 1998; 51: 129-135
Heinemann LAJ, Garbe E. Third generation oral contraceptives and the risk of venous
thromboembolism. Middle East Fertility Society Journal 1998; 3: 29-34
Garbe E, LeLorier J, Suissa S. Association of inhaled corticosteroid use with cataract
extraction in elderly patients. JAMA 1998; 280: 539-543
Garbe E, Müller-Oerlinghausen B. [Foreign databases for research after drug licensing. A
model also for Germany?] Deutsches Ärzteblatt 1998; 49: 3138-3143
Heinemann LAJ, Garbe E, Claßen E, Willich SN, Barth W, Thiel C. [Trends in cardiovascular
risk factor profiles in East Germany. Three independent population studies as part of the
project MONICA East Germany]. Deutsche Medizinische Wochenschrift 1998, 123: 889-895
Garbe E, LeLorier J, Suissa S. Exposure to allopurinol and the risk of cataract extraction in
elderly patients. Archives of Ophthalmology 1998,116: 1652-1656
Heinemann LAJ , Barth W, Garbe E, Willich SN, Kunze K und die Forschungsgruppe
MONICA Ostdeutschland. [Epidemiologic data of stroke. Data of the WHO-MONICA Project
in Germany]. Nervenarzt 1998, 69: 1091-1099
Garbe E, LeLorier J, Boivin J, Suissa S. Inhaled and nasal glucocorticoids and the risks of
ocular hypertension or open-angle glaucoma. JAMA 1997; 277: 722-727
Garbe E, LeLorier J, Boivin J, Suissa S. Risk of ocular hypertension or open-angle glaucoma
in elderly patients on oral glucocorticoids. Lancet 1997; 350: 979-982
Heinemann LAJ, DoMinh T, Guggenmoos-Holzmann I, Thiel C, Garbe E (manuscript
prepared for the collaborative MILTS Project Team). Oral contraceptives and liver cancer.
Results of the Multicentre International Liver Tumor Study (MILTS). Contraception 1997, 56:
275-284
Garbe C, Weiss J, Krüger S, Garbe E et al. The German melanoma registry and
environmental risk factors implied. Recent Results in Cancer Research 1993; 128: 69-89
Garbe E, Röhmel J, Gundert-Remy U. Clinical and statistical issues for therapeutic
equivalence trials. Eur J Clin Pharmacol 1993; 45: 1-7
LETTERS:
Andersohn F, Suissa S, Garbe E. Biphasic fracture risk in diabetes: A population-based
study. Bone 2008; 42: 235
Scharnetzky E, Schill W, Garbe E. Long-term mortality associated with aprotinin following
coronary artery bypass graft surgery (letter). JAMA 2007; 297: 2475
Andersohn F, Suissa S, Garbe E. Cyclooxygenase inhibitors and cardiovascular risk (letter).
JAMA 2007; 297: 586-7
Andersohn F, Suissa S, Garbe E. Risks and benefits of celecoxib to prevent colorectal
adenomas (letter). N Engl J Med 2006; 355: 2371
Scharnetzky E, Andersohn F, Schill W, Garbe E, Pigeot I. Wie viele durch Rofecoxib
Geschädigte in Deutschland (letter)? Med Klin 2006; 101; 675-676
Garbe E, Suissa S. Risks of postmenopausal hormone replacement (letter). JAMA 2002;
288: 2822.
Clark P, Garbe E, Habbick B, Lawrence V, Spitzer WO. Questions on breast-implants study
(letter). Lancet 1998, 351: 1358-1359
Suissa S, Garbe E. Risk of hypoglycemia with antihypertensive medication (letter). JAMA
1997, 278: 1570
Garbe E, Suissa S. Inhaled glucocorticoids and the risk of cataracts (letter). N Engl J Med
1997; 337: 1555
BOOK CHAPTERS:
Garbe E. Nutzung von Sekundärdaten für ein Versorgungsmonitoring: zur Notwendigkeit
einer Validierung. In: Kurth BM (Ed.) Monitoring der gesundheitlichen Versorgung in
Deutschland. Konzepte, Anforderungen, Datenquellen. Report Versorgungsforschung.
Deutscher Ärzteverlag 2008: 49-56
Garbe E. Sex-related Differences in Pharmacokinetics and Drug Effects. In: Regitz-Zagrosek
V, Fuchs J (Eds): Geschlechterforschung in der Medizin. Peter Lang Verlag Frankfurt am
Main 2006: 49-67
Garbe E, Suissa S. Pharmacoepidemiology. In: Ahrens W, Pigeot I (Eds): Handbook of
Epidemiology. Springer Verlag Berlin 2005: 1225-1266
Hasford J, Schubert I, Garbe E, Dietlein G, Glaeske G. Memorandum to usefulness and
necessity of pharmacoepidemiological databases in Germany (Memorandum zu Nutzen und
Notwendigkeit pharmakoepidemiologischer Datenbanken in Deutschland.) Berlin – Bremen –
Frankfurt – Köln – München 2004
Garbe E. Pharmacoepidemiological analysis of ocular hypertension, open-angle glaucoma
and cataract as adverse effects of glucocorticoids (Pharmakoepidemiologische Analyse zu
okulärer Hypertension, Offenwinkelglaukom und Katarakt als unerwünschte Wirkungen von
Glukokortikoiden). Habilitation thesis Charité 2000
Heinemann LAJ, Garbe E. Cardiovascular Risks Associated with Oral Contraceptives. In:
Rabe T, Runnebaum B (eds.). Fertility Control – Update and Trends. Springer Verlag Berlin
Heidelberg 1999: 91-119
Garbe E. Malignant melanoma in the central registry of the German Dermatological Society
(Das maligne Melanom im Zentralregister der Deutschen Dermatologischen Gesellschaft).
Dissertation thesis in medicine. Free University Berlin 1991